866-997-4948(US-Canada Toll Free)

PharmaPoint: Obesity - France Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 113 Pages

PharmaPoint: Obesity - France Drug Forecast and Market Analysis to 2022

Summary

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

The French obesity drug market was valued at approximately $41m in 2012. The market is a severely underserved space, with only Xenical and its generic as the sole therapy for chronic weight management. Due to the high cost of therapy, most patients have been taking generic orlistat. With a progressively more expansive view on the treatment of obesity with pharmacological intervention, GlobalData forecasts the arrival of two promising therapies in 2015.

Scope

- Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in France from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the France Obesity market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in France.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 17
3.1.3 Prognosis 17
3.1.4 Quality of Life 18
3.2 Symptoms 18
4 Disease Management 19
4.1 Treatment Overview 19
4.2 France 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 26
5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 33
5.3 Product Profiles: Drugs 35
5.3.1 Xenical (orlistat) 35
5.3.2 Belviq (lorcaserin) 38
5.3.3 Oblean (cetilistat) 43
6 Opportunity and Unmet Need 46
6.1 Overview 46
6.2 A Drug with Greater Than 10% Average Weight Loss 47
6.2.1 Unmet Need 47
6.2.2 Gap Analysis 48
6.2.3 Opportunity 49
6.3 A Drug with Increased Safety and Tolerability 49
6.3.1 Unmet Need 49
6.3.2 Gap Analysis 50
6.3.3 Opportunity 50
6.4 Reimbursement by Private and Public Payers 50
6.4.1 Unmet Need 50
6.4.2 Gap Analysis 52
6.4.3 Opportunity 52
6.5 Increased Physician Education 52
6.5.1 Unmet Need 52
6.5.2 Gap Analysis 53
6.5.3 Opportunity 53
6.6 Increased Drug-Treatment Rate 54
6.6.1 Unmet Need 54
6.6.2 Gap Analysis 54
6.6.3 Opportunity 55
6.7 Improved Guidelines 55
6.7.1 Unmet Need 55
6.7.2 Gap Analysis 56
6.7.3 Opportunity 56
6.8 Improved Approach to Diagnosis 56
6.8.1 Unmet Need 56
6.8.2 Gap Analysis 57
6.8.3 Opportunity 57
7 Pipeline Assessment 58
7.1 Overview 58
7.2 Promising Drugs in Clinical Development 61
7.2.1 Contrave 64
7.2.2 Victoza (liraglutide) 69
7.2.3 Velneperit 74
7.2.4 Empatic 78
8 Market Outlook 83
8.1 France 84
8.1.1 Forecast 84
8.1.2 Key Events 88
8.1.3 Drivers and Barriers 89
9 Appendix 91
9.1 Bibliography 91
9.2 Abbreviations 97
9.3 Research Methodology 99
9.4 Forecasting Methodology 99
9.4.1 Percent Drug-Treated Obesity Patients 100
9.4.2 Drugs Included in Each Therapeutic Class 100
9.4.3 Launch and Patent Expiry Dates 101
9.4.4 General Pricing Assumptions 101
9.4.5 Individual Drug Assumptions 102
9.4.6 Generic Erosion 105
9.4.7 Pricing of Pipeline Agents 105
9.5 Physicians, Specialists, and Payers Included in This Study 106
9.6 About the Authors 109
9.6.1 Analysts 109
9.6.2 Therapy Director - CVMD and Infectious Disease 110
9.6.3 Director - Medical Devices 110
9.6.4 Global Head of Healthcare 111
9.7 About GlobalData 112
9.8 Disclaimer 112

List of Table

1.1 List of Tables
Table 1: Target Pathways in the Treatment of Obesity 17
Table 2: Symptoms of Obesity 18
Table 3: Treatment Guidelines for Obesity 22
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 23
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 24
Table 6: Bariatric Treatment Attributes 32
Table 7: Leading Drug Treatments for Obesity, 2013 33
Table 8: Marketed Obesity Treatment Devices by Type 34
Table 9: Product Profile - Xenical 36
Table 10: Xenical SWOT Analysis, 2013 38
Table 11: Product Profile - Belviq 40
Table 12: Belviq SWOT Analysis, 2013 42
Table 13: Product Profile - Oblean 44
Table 14: ObleanSWOT Analysis, 2013 45
Table 15: Unmet Need and Opportunity in Obesity 47
Table 16: Endpoint Analysis of Clinical Trials Conducted in Obesity, 2013 60
Table 17: Obesity - Phase II-III Pipeline, 2013 61
Table 18: Comparison of Therapeutic Classes in Development for Obesity, 2013 63
Table 19: Obesity Treatment Pipeline Devices by Type 63
Table 20: Product Profile - Contrave 65
Table 21: Contrave SWOT Analysis, 2013 68
Table 22: Product Profile - Victoza 70
Table 23: Victoza SWOT Analysis, 2013 74
Table 24: Product Profile - Velneperit 75
Table 25: Velneperit SWOT Analysis, 2013 78
Table 26: Product Profile - Empatic 79
Table 27: Empatic SWOT Analysis, 2013 82
Table 28: Sales Forecasts ($) for Obesity in France, 2012-2022 86
Table 29: Key Events Impacting Sales for Obesity in France, 2012-2022 88
Table 30: Obesity Market in France - Drivers and Barriers, 2012-2022 89
Table 31: Key Launch Dates 101
Table 32: Key Patent Expiries 101

List of Chart

1.2 List of Figures
Figure 1: Treatment Algorithm for Obesity 21
Figure 2: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in France, 2012-2022 25
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012-2022 62
Figure 4: Sales for Obesity in France by Drug Class, 2012-2022 87

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *